TY - JOUR
T1 - Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia
AU - Velligan, Dawn
AU - Brenner, Ronald
AU - Sicuro, Franco
AU - Walling, David
AU - Riesenberg, Robert
AU - Sfera, Adonis
AU - Merideth, Charles
AU - Sweitzer, Dennis
AU - Jaeger, Judith
N1 - Funding Information:
This study was funded by AstraZeneca Pharmaceuticals. The sponsor was also responsible, with input and support from the investigators, for the design and implementation of the study, the analysis and interpretation of the data, the preparation of the study report, and the decision to publish. AstraZeneca also provided funding for editorial support.
PY - 2012/1
Y1 - 2012/1
N2 - AZD3480 is a selective agonist of α4β2 central neuronal nicotinic receptors (NNRs). This study investigated its effects on cognition, relative to placebo, in 440 patients with stable schizophrenia who were taking a single atypical antipsychotic medication and who were active cigarette smokers. Mean age was 41 (range 19 to 55) years and the majority of patients (88%) had a diagnosis of paranoid schizophrenia. Patients were randomized to one of 3 doses of AZD3480: 5. mg, 20. mg, and 35/100. mg (depending on CYP2D6 metabolic status), or to placebo. Treatment was given once daily for 12. weeks. The primary outcome measure was change in cognitive function from baseline to Week 12, as measured by IntegNeuro computerized test battery of cognitive function scores. Secondary outcome measures included assessment of functional capacity (University of California at San Diego Performance Based Skills Assessment [UPSA2]) and adaptive function (Social Functioning Scale [SFS]). AZD3480 failed to improve cognition relative to placebo in this population of patients or in subpopulations defined by disposition, metabolic status, antipsychotic treatment, age, age of illness onset, and sex. Likewise, no improvement relative to placebo was observed in either the SFS measure of adaptive functioning or the UPSA2 measure of functional capacity. AZD3480 was generally well tolerated in the population studied.
AB - AZD3480 is a selective agonist of α4β2 central neuronal nicotinic receptors (NNRs). This study investigated its effects on cognition, relative to placebo, in 440 patients with stable schizophrenia who were taking a single atypical antipsychotic medication and who were active cigarette smokers. Mean age was 41 (range 19 to 55) years and the majority of patients (88%) had a diagnosis of paranoid schizophrenia. Patients were randomized to one of 3 doses of AZD3480: 5. mg, 20. mg, and 35/100. mg (depending on CYP2D6 metabolic status), or to placebo. Treatment was given once daily for 12. weeks. The primary outcome measure was change in cognitive function from baseline to Week 12, as measured by IntegNeuro computerized test battery of cognitive function scores. Secondary outcome measures included assessment of functional capacity (University of California at San Diego Performance Based Skills Assessment [UPSA2]) and adaptive function (Social Functioning Scale [SFS]). AZD3480 failed to improve cognition relative to placebo in this population of patients or in subpopulations defined by disposition, metabolic status, antipsychotic treatment, age, age of illness onset, and sex. Likewise, no improvement relative to placebo was observed in either the SFS measure of adaptive functioning or the UPSA2 measure of functional capacity. AZD3480 was generally well tolerated in the population studied.
KW - AZD3480
KW - Cognitive dysfunction
KW - Neuronal nicotinic acetylcholine receptor
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=84155165109&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84155165109&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2011.10.004
DO - 10.1016/j.schres.2011.10.004
M3 - Article
C2 - 22088556
AN - SCOPUS:84155165109
SN - 0920-9964
VL - 134
SP - 59
EP - 64
JO - Schizophrenia research
JF - Schizophrenia research
IS - 1
ER -